CytoDyn reaches target enrollment for second interim analysis of Phase 3 COVID-19 trial
CytoDyn reaches target enrollment for second interim analysis of Phase 3 COVID-19 trial
SeekingAlpha
0 shares
1 views
You might like
Related news coverage
Russia Says Sputnik V COVID-19 Vaccine Over 95% Effective
HNGN
Russia's Sputnik V vaccine has been discovered to be over 95 percent effective against COVID-19 in the second interim analysis of..
-
NA Proactive news snapshot: Milestone Scientific, Loncor Resources, LeanLife, Genprex, BioSig Technologies UPDATE...
Proactive Investors
-
Humanigen showing positive results for cancer drug lenzilumab, also used to treat patients hospitalized with coronavirus
Proactive Investors
-
Russia's Sputnik V COVID-19 vaccine claimed to be 95 per cent effective
Mid-Day
-
NA Proactive news snapshot: CytoDyn, Humanigen, Killi, Great Panther Mining UPDATE…
Proactive Investors
Advertisement
More coverage
A year on, COVID-19 is still an unsolved mystery
Mid-Day
The first case of novel Coronavirus -- SARS-CoV2 -- was reported on November 17, 2019, in China's Wuhan city, and in March, the WHO..
-
CytoDyn partners with The Foundation for AIDS Research to test leronlimab as researchers advance toward HIV cure
Proactive Investors
-
NA Proactive news snapshot: Blackrock Gold, Alpine 4 Technologies, Loncor Resources, Bam Bam Resources, Nabis Holdings, Fireweed Zinc UPDATE…
Proactive Investors
-
NA Proactive news snapshot: Algernon Pharmaceuticals, African Gold Group , CytoDyn, RideShare Rental …
Proactive Investors
-
CytoDyn enlists 293 patients for second interim analysis of leronlimab in Phase 3 COVID-19 trial
Proactive Investors